Sign In
Buy ILMN
Illumina Earnings Calls
| Release date | Apr 30, 2026 |
| EPS estimate | $1.05 |
| EPS actual | $1.15 |
| EPS Surprise | 9.52% |
| Revenue estimate | 1.073B |
| Revenue actual | 1.091B |
| Revenue Surprise | 1.66% |
| Release date | Feb 05, 2026 |
| EPS estimate | $1.24 |
| EPS actual | $1.35 |
| EPS Surprise | 8.87% |
| Revenue estimate | 1.119B |
| Revenue actual | 1.159B |
| Revenue Surprise | 3.60% |
| Release date | Oct 30, 2025 |
| EPS estimate | $1.17 |
| EPS actual | $1.34 |
| EPS Surprise | 14.53% |
| Revenue estimate | 1.065B |
| Revenue actual | 1.083B |
| Revenue Surprise | 1.65% |
| Release date | Jul 30, 2026 |
| EPS estimate | $1.24 |
| EPS actual | - |
| Revenue estimate | 1.131B |
| Revenue actual | - |
| Expected change | +/- 3.84% |
Last 4 Quarters for Illumina
Below you can see how ILMN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 30, 2026 |
| Price on release | - |
| EPS estimate | $1.24 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jun 15, 2026 | $166.89 |
| Jun 16, 2026 | $164.28 |
| Jun 17, 2026 | $159.09 |
| Jun 18, 2026 | $161.93 |
| Jun 22, 2026 | $161.38 |
| Release date | Oct 30, 2025 |
| Price on release | $99.01 |
| EPS estimate | $1.17 |
| EPS actual | $1.34 |
| EPS surprise | 14.53% |
| Date | Price |
|---|---|
| Oct 24, 2025 | $100.11 |
| Oct 27, 2025 | $100.35 |
| Oct 28, 2025 | $97.80 |
| Oct 29, 2025 | $95.03 |
| Oct 30, 2025 | $99.01 |
| Oct 31, 2025 | $123.54 |
| Nov 03, 2025 | $119.99 |
| Nov 04, 2025 | $116.86 |
| Nov 05, 2025 | $122.44 |
| 4 days before | -1.10% |
| 4 days after | 23.66% |
| On release day | 24.78% |
| Change in period | 22.31% |
| Release date | Feb 05, 2026 |
| Price on release | $133.61 |
| EPS estimate | $1.24 |
| EPS actual | $1.35 |
| EPS surprise | 8.87% |
| Date | Price |
|---|---|
| Jan 30, 2026 | $144.81 |
| Feb 02, 2026 | $141.13 |
| Feb 03, 2026 | $135.43 |
| Feb 04, 2026 | $134.19 |
| Feb 05, 2026 | $133.61 |
| Feb 06, 2026 | $119.72 |
| Feb 09, 2026 | $117.25 |
| Feb 10, 2026 | $119.32 |
| Feb 11, 2026 | $116.38 |
| 4 days before | -7.73% |
| 4 days after | -12.90% |
| On release day | -10.40% |
| Change in period | -19.63% |
| Release date | Apr 30, 2026 |
| Price on release | $126.74 |
| EPS estimate | $1.05 |
| EPS actual | $1.15 |
| EPS surprise | 9.52% |
| Date | Price |
|---|---|
| Apr 24, 2026 | $127.88 |
| Apr 27, 2026 | $128.52 |
| Apr 28, 2026 | $126.92 |
| Apr 29, 2026 | $120.37 |
| Apr 30, 2026 | $126.74 |
| May 01, 2026 | $135.78 |
| May 04, 2026 | $139.37 |
| May 05, 2026 | $139.07 |
| May 06, 2026 | $142.58 |
| 4 days before | -0.89% |
| 4 days after | 12.50% |
| On release day | 7.13% |
| Change in period | 11.50% |
Illumina Earnings Call Transcript Summary of Q1 2026
Illumina delivered a strong start to 2026: Q1 revenue of $1.09B (+4.8% YoY), non-GAAP EPS of $1.15 (+19% YoY) and gross / operating margin expansion that exceeded guidance. Key drivers were robust NovaSeq X instrument placements (over 80 in Q1, supply-constrained), accelerating clinical sequencing consumables (clinical consumables growth ~20% ex-China for the second quarter in a row) and the completed SomaLogic acquisition (closed Jan 30). Management raised full-year 2026 guidance modestly (revenue to $4.52–4.62B; non-GAAP EPS to $5.15–5.30) and increased operating margin expectations, while authorizing an additional $1.5B share repurchase program. Near-term headwinds include inflationary pressures (components, freight) and continued weakness in research/applied consumables due to funding uncertainty, but management expects mitigations to drive margin improvement in H2 and reiterated progress toward 2027 targets (high-single-digit revenue growth, margin expansion, double-digit EPS growth). Strategic highlights: continued innovation and roadmap for NovaSeq X (new flow cells, higher throughput and quality), launch of TruPath and upcoming spatial transcriptomics, scaling of BioInsight/data initiatives (Billion Cell Atlas), and sustained clinical adoption driving higher sequencing intensity and consumables pull-through.
